Assessment of crucial pathways in validation cohort
The subproject TP 2B serves within the SYS-GLIO network as a central hub for the clinical evaluation of new diagnostic, prognostic and predictive molecular biomarkers and pathomechanistic models, resulting from the integrative bioinformatic analysis and the subsequent systems biology modeling on the basis of the analysis results of the consortium high-throughput data. The goal of TP 2B is the clarification of the clinical relevance of the in the basic sciences and systems biology obtained new findings of the subprojects. The potential diagnostic, prognostic or predictive clinical role of newly identified candidate genes or gene signatures for personalized diagnosis and treatment of patients with malignant gliomas should be clarified, including in particular the possible role for improved prediction of malignant progression and development of resistance to cytotoxic therapies. New, clinically promising markers should be then translated to the clinical routine use.